Table 3 Predicted impact on renal function-based carboplatin dosing of a change from current practices to the new sampling times and correction factor recommended by BNMS
From: Estimation of renal function and its potential impact on carboplatin dosing in children with cancer
Existing sampling times (h) | Existing correction factor | New sampling times (h) | New correction factor | Number of centres | Percentage of children with >10% carboplatin dose change |
|---|---|---|---|---|---|
1, 2, 3 and 4 | None | 2,3 and 4 | BM | 1 | 72 |
1, 2 and 3 | None | 2,3 and 4 | BM | 3 | 80 |
2 and 4 | None | 2,3 and 4 | BM | 2 | 85 |
2, 3 and 4 | None | 2,3 and 4 | BM | 1 | 85 |
2, 3 and 4 | Chantler | 2,3 and 4 | BM | 2 | 15 |
2 and 4 | Chantler | 2,3 and 4 | BM | 3 | 15 |
1, 3 and 4 | BM | 2,3 and 4 | BM | 1 | 4 |
2 and 3 | BM | 2,3 and 4 | BM | 1 | 4 |
2, 3 and 4 | BM | 2,3 and 4 | BM | 5 | No change |
Others | — | 2,3 and 4 | BM | 2 | Not applicable |
